## 1,8-Dimethoxyphenazine: A Versatile Molecule for Research
1,8-Dimethoxyphenazine (1,8-DMP) is a heterocyclic compound with a distinctive phenazine core structure and two methoxy groups attached at positions 1 and 8. Its importance in research stems from its unique properties and applications in various fields.
**Here's a breakdown of its significance:**
**1. Antioxidant Properties:**
* 1,8-DMP exhibits strong antioxidant activity, scavenging free radicals and protecting against oxidative stress. This property makes it a potential candidate for therapeutic applications in neurodegenerative diseases, cardiovascular diseases, and cancer.
**2. Antimicrobial Activity:**
* 1,8-DMP demonstrates antimicrobial activity against a range of bacteria and fungi. Its ability to disrupt bacterial cell membranes and inhibit their growth makes it a promising lead compound for developing new antibiotics.
**3. Photophysical Properties:**
* 1,8-DMP exhibits strong fluorescence, making it useful in various fields, including:
* **Fluorescent probes:** Its photophysical properties make it an excellent candidate for creating fluorescent probes to monitor biological processes and detect specific molecules.
* **Organic light-emitting diodes (OLEDs):** Its strong fluorescence and high quantum yield make it a potential component in OLED devices.
**4. Dye Sensitized Solar Cells (DSSCs):**
* 1,8-DMP has been explored as a photosensitizer in DSSCs. Its ability to absorb sunlight and generate electrons can contribute to efficient energy conversion in these devices.
**5. Other Applications:**
* 1,8-DMP is also used in various research areas such as:
* **Material science:** As a building block for developing new materials with specific properties.
* **Biotechnology:** For developing novel diagnostic and therapeutic tools.
**Challenges and Future Research:**
* Despite its promising potential, 1,8-DMP faces challenges in its development for therapeutic applications.
* Further research is needed to understand its:
* **Toxicity and pharmacokinetics**
* **Mechanism of action in various applications**
* **Optimal synthetic routes and scalability**
**In summary:**
1,8-Dimethoxyphenazine is a versatile molecule with potential applications in various research fields. Its antioxidant, antimicrobial, photophysical, and other properties make it a valuable tool for developing new therapeutic agents, materials, and devices. However, more research is needed to overcome the challenges associated with its development and translate its potential into real-world applications.
ID Source | ID |
---|---|
PubMed CID | 4136929 |
CHEMBL ID | 1401841 |
CHEBI ID | 105598 |
SCHEMBL ID | 2373937 |
Synonym |
---|
MLS001003683 |
smr000347522 |
CHEBI:105598 |
1,8-dimethoxyphenazine |
AKOS003625534 |
HMS2685K03 |
phenazine, 1,8-dimethoxy- |
14265-35-1 |
SCHEMBL2373937 |
CHEMBL1401841 |
DTXSID70399756 |
Q27183350 |
SR-01000025242-1 |
sr-01000025242 |
Class | Description |
---|---|
phenazines | Any organonitrogen heterocyclic compound based on a phenazine skeleton and derivatives. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 22.3872 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 1.4092 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 37.9330 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 7.6006 | 0.0184 | 6.8060 | 14.1254 | AID624172; AID624417 |
BRCA1 | Homo sapiens (human) | Potency | 17.7828 | 0.8913 | 7.7225 | 25.1189 | AID624202 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 29.0810 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
USP1 protein, partial | Homo sapiens (human) | Potency | 39.8107 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
TDP1 protein | Homo sapiens (human) | Potency | 20.5962 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 12.9244 | 0.1800 | 13.5574 | 39.8107 | AID1460; AID1468 |
thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 19.9526 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 28.1838 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 79.4328 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 22.3872 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 3.5481 | 0.5406 | 17.6392 | 96.1227 | AID2528 |
thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 43.5350 | 0.0100 | 39.5371 | 1,122.0200 | AID1469; AID1567; AID1568; AID1570; AID1571; AID1572; AID1573 |
importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 45.8577 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
DNA polymerase beta | Homo sapiens (human) | Potency | 39.8107 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
flap endonuclease 1 | Homo sapiens (human) | Potency | 28.1838 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
ras-related protein Rab-9A | Homo sapiens (human) | Potency | 3.9811 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 29.9349 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
eyes absent homolog 2 isoform a | Homo sapiens (human) | Potency | 28.1838 | 1.1998 | 14.6419 | 50.1187 | AID488837 |
snurportin-1 | Homo sapiens (human) | Potency | 45.8577 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 35.4813 | 0.0103 | 23.8567 | 63.0957 | AID2662 |
GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 56.2341 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 27.0050 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
geminin | Homo sapiens (human) | Potency | 15.1962 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
Vpr | Human immunodeficiency virus 1 | Potency | 22.3872 | 1.5849 | 19.6264 | 63.0957 | AID651644 |
survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 19.9526 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 11.2202 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | Potency | 0.7943 | 0.7943 | 12.2693 | 31.6228 | AID1568 |
TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 22.3872 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 37.9330 | 0.0601 | 10.7453 | 37.9330 | AID485367 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, RNA-directed RNA polymerase NS5 | Dengue virus 2 16681-PDK53 | IC50 (µMol) | 100.0000 | 2.3700 | 54.1398 | 100.0000 | AID588689 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
recombinase A | Mycobacterium tuberculosis H37Rv | EC50 (µMol) | 22.4750 | 0.0180 | 23.2882 | 287.6000 | AID434968; AID435010 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Caspase 6, apoptosis-related cysteine peptidase | Homo sapiens (human) | AC50 | 23.0900 | 0.0636 | 11.2358 | 44.9700 | AID720632 |
replicative DNA helicase | Mycobacterium tuberculosis H37Rv | AC50 | 198.0650 | 0.0570 | 30.7482 | 325.3000 | AID449749; AID449750 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
RNA polymerase II cis-regulatory region sequence-specific DNA binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
DNA binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
double-stranded DNA binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
RNA binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
mRNA 3'-UTR binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
protein binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
lipid binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
identical protein binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
pre-mRNA intronic binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
molecular condensate scaffold activity | TAR DNA-binding protein 43 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
endoplasmic reticulum membrane | Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) |
plasma membrane | Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) |
intracellular non-membrane-bounded organelle | TAR DNA-binding protein 43 | Homo sapiens (human) |
nucleus | TAR DNA-binding protein 43 | Homo sapiens (human) |
nucleoplasm | TAR DNA-binding protein 43 | Homo sapiens (human) |
perichromatin fibrils | TAR DNA-binding protein 43 | Homo sapiens (human) |
mitochondrion | TAR DNA-binding protein 43 | Homo sapiens (human) |
cytoplasmic stress granule | TAR DNA-binding protein 43 | Homo sapiens (human) |
nuclear speck | TAR DNA-binding protein 43 | Homo sapiens (human) |
interchromatin granule | TAR DNA-binding protein 43 | Homo sapiens (human) |
nucleoplasm | TAR DNA-binding protein 43 | Homo sapiens (human) |
chromatin | TAR DNA-binding protein 43 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |